Hong Kong stocks are moving differently | SinoMab BioScience Limited (01244.HK) rises nearly 7% as EnVida receives orphan drug designation for gastric cancer and gastroesophageal junction cancer indications.

According to the Wisdom Finance APP, Sino Biopharmaceutical Limited (01244.HK) has risen by nearly 7%, as of the time of publication, it has increased by 6.77%, reaching 4.73 Hong Kong dollars, with a trading volume of 911,200 Hong Kong dollars.